Emalex Biosciences Closes $250M Financing Round
The series D funding round looks to fund a phase 3 clinical trial and commercialization of a new class of drug for patients with Tourette Syndrome.
After clicking on a story, use the back arrow in your browser to return to your search results. Use phrases "in quotes" or the tools below to better filter your results.